Loading
Life sciences · Phase 4 Trial
ClinicalTrials.gov · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 4 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06995144). This is a study registration, not published results. Lead sponsor: Sarfez Pharmaceuticals, Inc.. Recruitment status: WITHDRAWN. Phase: PHASE4. Study type: INTERVENTIONAL. Conditions: Heart Failure, Edema, Pulmonary Congestion, Fluid Overload. Interventions: DRUG: Extended Release Torsemide Tablets; DRUG: Immedate Release Torsemide Tablets. Primary outcome measures: Urinary sodium excretion measurement , 4-8 hours (post-lunch period). Brief summary: The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.